Back to Trades
Buy4
Artiva Biotherapeutics, Inc.
ARTV
Total Value
$75.0M
Net $75.0M bought
Purchases
$75.0M
1 transaction
Company Information
- Company Name
- Artiva Biotherapeutics, Inc.
- Ticker Symbol
- ARTV
- CIK
- 0001817241
Insider Information
- Role
- Insider
- Location
- BOSTON, MA
Filing Details
- Filing Date
- May 13, 2026
- Transaction Date
- May 11, 2026
- Accession Number
- 0001231919-26-000491
- Form Type
- 4
- Net Trading Amount
- $75.0M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| May 11, 2026 | Common Stock | 6,510,416 | $11.52 | Purchase | $75.0M |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| May 11, 2026 | Derivative | 2,170,138 | $0.00 | Purchase | $217 |
Footnotes
- (F1)RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- (F2)Held directly by the Fund.
- (F3)Held directly by the Nexus Fund.
- (F4)Held directly by Nexus Fund III.
- (F5)Held directly by the Account.
- (F6)The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Fund shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Fund, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.